Evidence map›Paper›PMID 25586651›Full record

GuidelineJournal of gastroenterology2015

Evidence-based clinical practice guidelines for functional dyspepsia.

Hiroto Miwa, Motoyasu Kusano, Tomiyasu Arisawa, Tadayuki Oshima, Mototsugu Kato, Takashi Joh, Hidekazu Suzuki, Kazunari Tominaga, Koji Nakada, Akihito Nagahara and 12 more

Open access · bronzeAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 7 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 7 syntheses or guidelines pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a DClinical pharmacology in drug development · 2022
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Eosinophil and Mast Cell Counts in the Stomach and Duodenum of Patients with Functional Dyspepsia without aThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022
    Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Hiroto MiwaGuidelines Committee for creating and evaluating the "Evidence-based clinical practice guidelines for functional dyspepsia", the Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13 Ginza, Chuo, Tokyo, 104-0061, Japan, miwahgi@hyo-med.ac.jp.
Motoyasu Kusano
Tomiyasu Arisawa
Tadayuki Oshima
Mototsugu Kato
Takashi Joh
Hidekazu Suzuki
Kazunari Tominaga
Koji Nakada
Akihito Nagahara
Seiji Futagami
Noriaki Manabe
Akio Inui
Ken Haruma
Kazuhide Higuchi
Koji Yakabi
Michio Hongo
Naomi Uemura
Yoshikazu Kinoshita
Kentaro Sugano
Tooru Shimosegawa
Japanese Society of Gastroenterology
The Japanese Society of Gastroenterological Surgery · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

General interest in functional gastrointestinal disorders is increasing among Japanese doctors as well as patients. This increase can be attributed to a number of factors, including recent increased interest in quality of life and advances in our understanding of the pathophysiology of gastrointestinal disease. Japan recently became the world's first country to list "functional dyspepsia" as a disease name for national insurance billing purposes. However, recognition and understanding of functional dyspepsia (FD) remain poor, and no standard treatment strategy has yet been established. Accordingly, the Japanese Society of Gastroenterology (JSGE) developed an evidence-based clinical practice guideline for FD, consisting of five sections: concept, definition, and epidemiology; pathophysiology; diagnosis; treatment; and prognosis and complications. This article summarizes the Japanese guideline, with particular focus on the treatment section. Once a patient is diagnosed with FD, the doctor should carefully explain the pathophysiology and benign nature of this condition, establish a good doctor-patient relationship, and then provide advice for daily living (diet and lifestyle modifications, explanations, and reassurance). The proposed pharmacological treatment is divided into two steps: initial treatment including an acid inhibitory drug (H2RA or PPI) or prokinetics, (strong recommendation); second-line treatment including anxiolytics, antidepressants, and Japanese traditional medicine (weak recommendation). H. pylori eradication, strongly recommended with a high evidence level, is positioned separately from other treatment flows. Conditions that do not respond to these treatment regimens are regarded as refractory FD. Patients will be further examined for other organic disorders or will be referred to specialists using other approaches such as psychosomatic treatment.

Indexed as

AlgorithmsComplementary TherapiesDiagnostic Techniques, Digestive SystemDyspepsiaEvidence-Based MedicineGastrointestinal AgentsHumansPrevalencePrognosisTerminology as TopicGastrointestinal Agents

Identifiers

PMID25586651
OpenAlexW2070454353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.